Oxford–AstraZeneca COVID-19 vaccine

Human medicines European public assessment report (EPAR): VidPrevtyn Beta, COVID-19 Vaccine (recombinant, adjuvanted), Date of authorisation: 10/11/2022, Revision: 2, Status: Authorised

Retrieved on: 
Tuesday, January 2, 2024
People, Chills, Medical Subject Headings, Diarrhea, Marketing, Immunodeficiency, Pregnancy, Agency, INN, Risk, Immune system, Fever, Fatigue, Lymph, Sanofi–GSK COVID-19 vaccine, Allergy, ATC, Messenger, Antibody, EMA, Pain, International, Vaccine, Headache, Disease, Ageing, Language, Vaccination, Swelling, Pfizer–BioNTech COVID-19 vaccine, Hypersensitivity, Oxford–AstraZeneca COVID-19 vaccine, COVID-19, European Medicines Agency, SARS-CoV-2, Select, Patient, Bruise, Safety, Anatomy, IIA

Human medicines European public assessment report (EPAR): VidPrevtyn Beta, COVID-19 Vaccine (recombinant, adjuvanted), Date of authorisation: 10/11/2022, Revision: 2, Status: Authorised

Key Points: 


Human medicines European public assessment report (EPAR): VidPrevtyn Beta, COVID-19 Vaccine (recombinant, adjuvanted), Date of authorisation: 10/11/2022, Revision: 2, Status: Authorised

New partnership aims to advance vaccine against MERS coronavirus

Retrieved on: 
Thursday, December 21, 2023
Epidemic, Partnership, Immune system, University of Oxford, Infection, PRIME, EMA, Urinary tract infection, Barinthus, WHO, Oxford–AstraZeneca COVID-19 vaccine, Vaccine, MERS, MERS-related coronavirus, CEPI, Vaccination, Coalition, Clinical trial, Cancer, University, ChAdOx1, COVID-19, European Medicines Agency, Policy, Public, Coronavirus, Phase II, Medicine, Public health, Autoimmunity, Pharmaceutical industry

“We had a head-start in our development of the Oxford/AstraZeneca COVID-19 vaccine, thanks to the many years already spent researching a vaccine for another coronavirus, MERS.

Key Points: 
  • “We had a head-start in our development of the Oxford/AstraZeneca COVID-19 vaccine, thanks to the many years already spent researching a vaccine for another coronavirus, MERS.
  • “There is an active need for a MERS vaccine for at-risk populations and travellers in the Middle East.
  • MERS is a severe respiratory infection caused by MERS-CoV, a coronavirus that was first identified in 2012 in Saudi Arabia.
  • The vaccine will be made available to low- and middle-income countries at a price no higher than the cost of manufacturing plus 10 percent.

Vaccitech Renames as Barinthus Biotherapeutics to Highlight Strategic Evolution into a T Cell Immunotherapy Company Targeting Chronic Infectious Diseases, Autoimmunity, and Cancer

Retrieved on: 
Monday, November 6, 2023
Avalon, Modified vaccinia Ankara, Autoimmunity, American Association for Cancer Research, Hepatology, Vaccine, Liver, Immunogenicity, LDN, PD-1, University, CHB, Research, Barinthus, Immune system, COVID-19, Efficacy, MVA, Hepatitis, Repeat, Hepatitis B, Infection, Cancer, HBsAg, Patient, Asian Liver Center, HBV, AASLD, Pharmaceutical industry, Oxford–AstraZeneca COVID-19 vaccine, Safety

The company also announced today that it has changed its name to Barinthus Biotherapeutics plc to represent the evolution and expansion of its focus beyond vaccines. The company expects to begin trading under its new name and ticker (Nasdaq: BRNS) effective as of November 7, 2023. As part of the rebranding, the company has also updated its website -- learn more at www.barinthusbio.com.

Key Points: 
  • The company also announced today that it has changed its name to Barinthus Biotherapeutics plc to represent the evolution and expansion of its focus beyond vaccines.
  • The company expects to begin trading under its new name and ticker (Nasdaq: BRNS) effective as of November 7, 2023.
  • As part of the rebranding, the company has also updated its website -- learn more at www.barinthusbio.com .
  • “Today the company is focused on the development of novel T cell immunotherapeutic candidates, which evolved out of that initial vaccine research.

Winner of 2023 ISPE Facility of the Year Awards to be Announced at Black Tie Banquet

Retrieved on: 
Thursday, October 12, 2023
Nexus, COVID-19, Genentech, ISPE, Engineering, International Society, Vaccine, Development, CSC, Pharma, Safety, Carbon, LAS, Oxford–AstraZeneca COVID-19 vaccine, Medication, COVID-19 vaccine, Automotive Executive of the Year Award, Wuxi, Patient, Medical device, Pharmaceutical industry, Fine chemical

LAS VEGAS, Oct. 12, 2023 /PRNewswire-PRWeb/ -- ISPE is set to unveil the recipient of the prestigious 2023 Facility of the Year Award (FOYA) Overall Winner during the upcoming FOYA Celebratory Reception and Banquet on 15 October 2023, in Las Vegas, Nevada, USA. The event will showcase the overall winner and recognize the accomplished FOYA category winners. Acceptance speeches will also be given by honorees.

Key Points: 
  • LAS VEGAS, Oct. 12, 2023 /PRNewswire-PRWeb/ -- ISPE is set to unveil the recipient of the prestigious 2023 Facility of the Year Award (FOYA) Overall Winner during the upcoming FOYA Celebratory Reception and Banquet on 15 October 2023, in Las Vegas, Nevada, USA.
  • The event will showcase the overall winner and recognize the accomplished FOYA category winners.
  • "Each of these companies and their associated projects represent manufacturing facilities of the future in pharmaceutical industry," said Tom Hartman, President and CEO of ISPE.
  • : Based in Pleasant Prairie, Wisconsin, USA, Project Tomorrow showcases Nexus Pharmaceuticals' consistent focus on meeting patient needs for the long term.

Oxford Science Enterprises Raises £250 Million

Retrieved on: 
Monday, July 18, 2022
COVAX, Climate change, Research, Moa, University, ORCA (computer system), Cancer, Infection, Investment, University of Oxford, Nasdaq, Time, First Light, Technology, Oxford–AstraZeneca COVID-19 vaccine, Environment, Johnson Health Tech, Initial public offering, ORCA, Herbicide, Food security, Company, List of life sciences, OSE, Health, Deep tech, Heart failure, Degenerative disease, Partnership, Therapy, COVID-19, Exact sciences, Vaccine, Genomics, Pharmaceutical industry, Renewable energy, Vaccitech

OXFORD, England, July 18, 2022 /PRNewswire/ -- Oxford Science Enterprises (OSE), the independent investment company created to found, fund and build transformational businesses via its unique partnership with the University of Oxford, today announces it has raised a further £250 million ($300 million) in funding. This brings the total amount raised by OSE to more than £850 million (>$1 billion) since inception in 2015.

Key Points: 
  • OXFORD, England, July 18, 2022 /PRNewswire/ -- Oxford Science Enterprises (OSE), the independent investment company created to found,fund and buildtransformational businesses viaits unique partnership with the University of Oxford, today announces it has raised a further 250 million ($300 million) in funding.
  • This brings the total amount raised by OSE to more than 850 million (>$1 billion) since inception in 2015.
  • Oxford Science Enterprises (OSE) is an independent, billion-pound investment company, created in 2015 to found, fund and build transformational businesses via its unique partnership with the University of Oxford, the world's #1 research university.
  • To date, OSE has invested 0.5 billion in over 80 ambitious companies built on Oxford science.

Oxford Science Enterprises Raises £250 Million

Retrieved on: 
Monday, July 18, 2022
COVAX, Climate change, Research, Moa, University, ORCA (computer system), Cancer, Infection, Investment, University of Oxford, Nasdaq, Time, First Light, Technology, Oxford–AstraZeneca COVID-19 vaccine, Environment, Johnson Health Tech, Initial public offering, ORCA, Herbicide, Food security, Company, List of life sciences, OSE, Health, Deep tech, Heart failure, Degenerative disease, Partnership, Therapy, COVID-19, Exact sciences, Vaccine, Genomics, Pharmaceutical industry, Renewable energy, Vaccitech

OXFORD, England, July 18, 2022 /PRNewswire/ -- Oxford Science Enterprises (OSE), the independent investment company created to found, fund and build transformational businesses via its unique partnership with the University of Oxford, today announces it has raised a further £250 million ($300 million) in funding. This brings the total amount raised by OSE to more than £850 million (>$1 billion) since inception in 2015.

Key Points: 
  • OXFORD, England, July 18, 2022 /PRNewswire/ -- Oxford Science Enterprises (OSE), the independent investment company created to found,fund and buildtransformational businesses viaits unique partnership with the University of Oxford, today announces it has raised a further 250 million ($300 million) in funding.
  • This brings the total amount raised by OSE to more than 850 million (>$1 billion) since inception in 2015.
  • Oxford Science Enterprises (OSE) is an independent, billion-pound investment company, created in 2015 to found, fund and build transformational businesses via its unique partnership with the University of Oxford, the world's #1 research university.
  • To date, OSE has invested 0.5 billion in over 80 ambitious companies built on Oxford science.

$2.34 Billion Viral Vector and Plasmid DNA Manufacturing Markets, 2027 - ResearchAndMarkets.com

Retrieved on: 
Wednesday, March 30, 2022
Health, Biotechnology, Treatment, CAGR, Organization, Colon, USD, DNA, Korea Disease Control and Prevention Agency, Clinical trial, Kidney, AAV, Skin, Plasmid, Infection, Lentivirus, Vaccine, Liver, Breast, Research, Dove Medical Press, Application, Camptothecin, Genetic disorder, Degenerative disease, Hypertension, Cardiovascular disease, Death, Cystic fibrosis, Incidence, Tissue, Prevalence, AIDS, Safety, COVID-19, Brain, Diosynth, Oxford–AstraZeneca COVID-19 vaccine, Thermo Fisher Scientific, Center, Lists of diseases, Breast cancer, Janssen Pharmaceuticals, Oncolytic virus, Patient, Johnson & Johnson, Pharmaceutical industry, Cancer, Growth

The "Viral Vector and Plasmid DNA Manufacturing Market - Growth, Trends, COVID-19 Impact, and Forecasts (2022 - 2027)" report has been added to ResearchAndMarkets.com's offering

Key Points: 
  • The "Viral Vector and Plasmid DNA Manufacturing Market - Growth, Trends, COVID-19 Impact, and Forecasts (2022 - 2027)" report has been added to ResearchAndMarkets.com's offering
    The viral vector and plasmid DNA manufacturing market is projected to reach USD 2,344.29 million by 2027, registering a CAGR of 23.38 % during the forecast period (2022-2027).
  • The COVID-19 outbreak is expected to positively impact the viral vector and plasmid DNA manufacturing market.
  • The AdVac viral vector technology could provide a potent and long-lasting humoral and cellular immune response to the body.
  • Several clinical studies are being conducted on viral vectors and plasmid DNA manufacturing, emphasizing the potential of gene therapy to address important medical needs.

Bill & Melinda Gates Foundation and Wellcome Pledge US$300 Million to CEPI for COVID-19 Pandemic Response and to Accelerate Epidemic Preparedness

Retrieved on: 
Tuesday, January 18, 2022
Ebola, Research, Republic, Coalition, Vaccine, R, Poverty, COVID-19 vaccine, TB, World Economic Forum, CEPI, Bill & Melinda Gates Foundation, COVID-19, Foundation, Science, Death, Northeastern University, Hunger, Mental health, Melinda Gates, World, Oxford–AstraZeneca COVID-19 vaccine, Pandemic, Global health, Health, Infection, HIV, Nipa, Epidemic, WHO, Bill, Risk, World Health Organization, Lists of countries and territories, United Kingdom, Life, Organization, Coronavirus, Investment, Pharmaceutical industry, Wellcome, Zika fever

SEATTLE and LONDON, Jan. 18, 2022 /PRNewswire/ -- Today the Bill & Melinda Gates Foundation and Wellcome each pledged US$150 million for a total of US$300 million to the Coalition for Epidemic Preparedness Innovations (CEPI), a global partnership launched five years ago this week by the governments of Norway and India, the Gates Foundation, Wellcome, and the World Economic Forum. The pledges come ahead of a global replenishment conference in March to support CEPI's visionary five-year plan to better prepare for, prevent, and equitably respond to future epidemics and pandemics.

Key Points: 
  • Five years ago, following the Ebola and Zika epidemics, our foundation helped launch CEPI.
  • "Wellcome proudly founded CEPI in 2017 along with partners from Norway, India, the Bill & Melinda Gates Foundation, and the World Economic Forum following the devastating 201416 Ebola epidemic.
  • Guided by the belief that every life has equal value, the Bill & Melinda Gates Foundation works to help all people lead healthy, productive lives.
  • Based in Seattle, Washington, the foundation is led by CEO Mark Suzman, under the direction of Bill Gates and Melinda French Gates.

Bill & Melinda Gates Foundation and Wellcome Pledge US$300 Million to CEPI for COVID-19 Pandemic Response and to Accelerate Epidemic Preparedness

Retrieved on: 
Tuesday, January 18, 2022
Ebola, Research, Republic, Coalition, Vaccine, R, Poverty, COVID-19 vaccine, TB, World Economic Forum, CEPI, Bill & Melinda Gates Foundation, COVID-19, Foundation, Science, Death, Northeastern University, Hunger, Mental health, Melinda Gates, World, Oxford–AstraZeneca COVID-19 vaccine, Pandemic, Global health, Health, Infection, HIV, Nipa, Epidemic, WHO, Bill, Risk, World Health Organization, Lists of countries and territories, United Kingdom, Life, Organization, Coronavirus, Investment, Pharmaceutical industry, Wellcome, Zika fever

SEATTLE and LONDON, Jan. 18, 2022 /PRNewswire/ -- Today the Bill & Melinda Gates Foundation and Wellcome each pledged US$150 million for a total of US$300 million to the Coalition for Epidemic Preparedness Innovations (CEPI), a global partnership launched five years ago this week by the governments of Norway and India, the Gates Foundation, Wellcome, and the World Economic Forum. The pledges come ahead of a global replenishment conference in March to support CEPI's visionary five-year plan to better prepare for, prevent, and equitably respond to future epidemics and pandemics.

Key Points: 
  • Five years ago, following the Ebola and Zika epidemics, our foundation helped launch CEPI.
  • "Wellcome proudly founded CEPI in 2017 along with partners from Norway, India, the Bill & Melinda Gates Foundation, and the World Economic Forum following the devastating 201416 Ebola epidemic.
  • Guided by the belief that every life has equal value, the Bill & Melinda Gates Foundation works to help all people lead healthy, productive lives.
  • Based in Seattle, Washington, the foundation is led by CEO Mark Suzman, under the direction of Bill Gates and Melinda French Gates.

Wego And Saudi Tourism Authority Form Strategic Partnership to Promote Tourism to Saudi

Retrieved on: 
Wednesday, January 12, 2022
City, Technology, STA, Vaccine, RT, COVID-19, Population, Season, Tourism, Pfizer–BioNTech COVID-19 vaccine, Wego, AstraZeneca, Culture, Little League World Series (Middle East-Africa Region), Multimedia, Quarantine, Partnership, Restaurant, Awareness, Online shopping, Oxford–AstraZeneca COVID-19 vaccine

DUBAI, UAE, Jan. 12, 2022 /PRNewswire/ -- Wego, the largest online travel marketplace in the Middle East and North Africa (MENA), and Saudi Tourism Authority (STA) have announced a strategic partnership to inspire Middle East holidaymakers to visit Saudi after more than a year of hiatus.

Key Points: 
  • DUBAI, UAE, Jan. 12, 2022 /PRNewswire/ -- Wego, the largest online travel marketplace in the Middle East and North Africa (MENA), and Saudi Tourism Authority (STA) have announced a strategic partnership to inspire Middle East holidaymakers to visit Saudi after more than a year of hiatus.
  • Mamoun Hmedan, Chief Commercial Officer and Managing Director, MENA and India, Wego, said: "We're excited to embark on this partnership with the Saudi Tourism Authority.
  • This new collaboration reflects our commitment to boost tourism in the region, to a destination that is unlike anywhere in the world.
  • Wego was founded in 2005 and is headquartered in Dubai and Singapore with regional operations in Bangalore Jakarta and Cairo.